Skip to Content

    Edwards Lifesciences’ Sapien 3 artificial heart valve, implanted through a catheter, is an alternative for heart disease patients whose conditions are bad enough to make surgery too risky. Over the past two years it’s been FDA approved for an increasing number of procedure types, including for repairing existing artificial valves that are breaking down. The com­pany’s growing footprint globally has driven strong sales abroad, where these kinds of minimally invasive heart procedures are becoming more popular. Edwards has been able to maintain at least a 24% net profit margin through the first half of 2017.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score2.7
    Sector
    Health Care
    Industry
    Medical Products and Equipment
    CEO
    Michael A. Mussallem
    Websitehttp://www.edwards.com
    Employees11,100
    HQ Location
    Irvine, Calif.
    Revenues ($M) (Past 12 Months)$3,232
    Profits ($M) (Past 12 Months)$716
    Market Value as of Oct. 9, 2017 ($M)$23,274